Discovery of Urea Derivatives of Celastrol as Selective Peroxiredoxin 1 Inhibitors against Colorectal Cancer Cells

• Published in: Journal of medicinal chemistry Vol. 67; no. 9; pp. 7176 - 7196
• Main Authors: Li, Yang, Zhu, Yuyuan, Shang, Fan-Fan, Xu, Lin, Jiang, Defang, Sun, Bin, Zhang, Lei, Luo, Cheng, Zhang, Ao, Zhang, Hao, Ding, Chunyong
• Format: Journal Article
• Language: English
• Published: WASHINGTON American Chemical Society 09.05.2024; Amer Chemical Soc
• Subjects: Chemistry, Medicinal; Life Sciences & Biomedicine; Pharmacology & Pharmacy; Science & Technology; INDUCE DIFFERENTIATION; APOPTOSIS; ACTIVATION; ROLES
• ISSN: 0022-2623; 1520-4804
• DOI: 10.1021/acs.jmedchem.4c00023

Peroxiredoxin (PRDX1) is a tumor-overexpressed antioxidant enzyme for eliminating excessive reactive oxygen species (ROS) to protect tumor cells from oxidative damage. Herein, a series of celastrol urea derivatives were developed based on its cocrystal structure with PRDX1, with the aim of pursuing a PRDX1-specific inhibitor. Among them, derivative 15 displayed potent anti-PRDX1 activity (IC50 = 0.35 μM) and antiproliferative potency against colon cancer cells. It covalently bound to Cys-173 of PRDX1 (K D = 0.37 μM), which was secured by the cocrystal structure of PRDX1 with an analogue of 15 while exhibiting weak inhibitory effects on PRDX2–PRDX6 (IC50 > 50 μM), indicating excellent PRDX1 selectivity. Treatment with 15 dose-dependently decreased the mitochondria membrane potential of SW620 cells, probably due to ROS induced by PRDX1 inhibition, leading to cell apoptosis. In colorectal cancer cell xenograft model, it displayed potent antitumor efficacy with superior safety to celastrol. Collectively, 15 represents a promising PRDX1 selective inhibitor for the development of anticolorectal cancer agents.